Atossa Therapeutics, Inc.
ATOS
$0.6231
$0.01812.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.84% | -5.13% | -5.23% | 5.69% | 11.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.97% | -3.31% | -2.12% | 4.08% | 13.34% |
| Operating Income | 11.97% | 3.31% | 2.12% | -4.08% | -13.34% |
| Income Before Tax | 15.25% | 9.79% | 18.04% | -4.34% | -11.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.25% | 9.79% | 18.04% | -4.34% | -11.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.25% | 9.79% | 18.04% | -4.34% | -11.62% |
| EBIT | 11.97% | 3.31% | 2.12% | -4.08% | -13.34% |
| EBITDA | 11.96% | 3.36% | 2.17% | -4.02% | -13.29% |
| EPS Basic | 15.09% | 9.11% | 17.34% | -4.94% | -12.02% |
| Normalized Basic EPS | 12.13% | 5.43% | 8.70% | 5.48% | -1.05% |
| EPS Diluted | 15.09% | 9.11% | 17.34% | -4.94% | -12.02% |
| Normalized Diluted EPS | 12.13% | 5.43% | 8.70% | 5.48% | -1.05% |
| Average Basic Shares Outstanding | -0.18% | -0.70% | -0.86% | -0.68% | -0.43% |
| Average Diluted Shares Outstanding | -0.18% | -0.70% | -0.86% | -0.68% | -0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |